Skip to NavigationSkip to content


Bayer buys out US-based Asklepios BioPharmaceutical in potential $4bn deal

Bayer has moved to bolster its cell and gene therapy (CGT) business through the acquisition of US biotech Asklepios BioPharmaceutical in an agreement valued at $4 billion. 

Bayer will make a payment of $2 billion upfront as part of the agreement, with an additional $2 billion available to Asklepios in developmental milestone payments, 75% of which are expected to be achieved within five years.

Covis Group to acquire AMAG Pharmaceuticals in $647m deal

Luxembourg-based Covis Group is set to acquire Massachusetts-based AMAG Pharmaceuticals in a new deal worth approximately $647 million on an enterprise basis, including debt, it has emerged.

The value of the deal translates to $13.75 per share, a premium of around 46% of AMAG’s common stock closing price as of 30 September.

Gilead scoops up Immunomedics in deal worth $21 billion

The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in cash, in a new deal which represents a valuation of the latter company at $21 billion.

The primary focus of the deal for Gilead is Immunomedics’ Trop-2 directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy), which it scoops up as part of the agreement.

Nestlé to acquire remaining shares in Aimmune for $2.6 billion

Food and drink giant Nestlé has confirmed it is in motion to scoop up the remaining shares in Californian biotech firm Aimmune in a deal valued at $2.6 billion, it has emerged.

This buyout comes after a number of investments from Nestlé to increase its share of the biotech over the years, beginning in 2016 with a payment of $145 million. This was followed in 2018 by a subsequent payment of £30 million as part of an initial public offering, as well as a further investment of $98 million.

Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal

Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share in cash, which brings the total valuation of the latter company to $4.9 billion.

The deal secured unanimous approval from both companies’ Boards of Directors and is expected to close in the second quarter of the year.

MSD set to acquire ArQule in deal worth up to $2.7 billion

MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, valued at $20 per share in cash.

ArQule is a company leveraging kinase inhibitor discovery in the pursuit of new treatments for cancer, among other conditions. The deal means that MSD scoops up the firm’s lead candidate ARQ 531, a Bruton’s tyrosine kinase (BTK) inhibitor currently in development at Phase 2 for the treatment of B-cell malignancies.

Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash

Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it has been revealed.

The move was unanimously approved by both companies’ Boards of Directors, with the proposed valuation equating to $60 per share – a premium of 110% to Audentes’ share price as of 2 December this year.

MSD scoops up biopharma firm Tilos for $773 million

US-based firm MSD has announced it intends to acquire biopharma firm Tilos Therapeutics, and has signed a deal with the company to this effect, valued to a total of $773 million.

This new deal means that MSD will acquire all outstanding shares of Tilos through a subsidiary, which altogether come to a potential consideration of $773 million, which includes both an upfront payment as well as milestone payments dependent on the achievement of certain developmental and commercial goals.

MSD buys Peloton Therapeutics in deal worth $2.1 billion

MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion.

US firm MSD will pay Texas-based biotech Peloton Therapeutics $1 billion upfront and a further $1.15 billion based on the achievement of regulatory and sales milestones.

The acquisition comes as MSD seeks to boost its oncology pipeline with the addition of Peloton’s lead candidate cancer drug PT2977.

Biogen boosts ophthalmology portfolio with $800m acquisition of gene therapy firm Nightstar

Biogen has announced it has inked an agreement to acquire clinical-stage gene therapy firm Nightstar for a total value of $800 million, which breaks down to $2.50 in cash per share after transaction expenses are taken into account.  

Based in London, Nightstar focuses on the development of adeno-associated virus (AAV) treatments for inherited retinal disorders.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches